相关实验视频
Updated: Feb 7, 2026

Surgical Models of Gastroesophageal Reflux with Mice
Published on: August 25, 2015
对转移性或复发性胃食道腺癌同时进行多种生物标志物测试的临床实施:单一机构的经验
U Okazaki1, I Nakayama1, N Sakamoto2
1Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
在临床实践中,对转移性胃食道腺癌 (mGEA) 进行多种生物标志物测试是可行的. 这种方法可以及时选择一线治疗,改善患者的治疗结果,并促进精确的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子诊断学 分子诊断
- 胃肠病学 胃肠病学
背景情况:
- 选择转移性胃食道腺癌 (mGEA) 的第一线治疗需要评估多种生物标志物,包括HER2,MMR,PD-L1和CLDN18.2.2.
- 瘤组织有限和测试的潜在延迟可能会阻碍及时启动治疗.
研究的目的:
- 评估在常规临床实践中对mGEA患者同时进行多个生物标志物测试的可行性.
- 评估综合生物标志物分析对一线治疗启动的影响.
主要方法:
- 对未经治疗的mGEA患者进行前性生物标志物测试的回顾性审查 (2022年4月至2023年10月).
- 同时检查八种生物标志物 (HER2,MMR,PD-L1,CLDN18.2,EBV,FGFR2,EGFR,MET) 使用活检或手术样本.
主要成果:
- 在203名mGEA患者中,在97.5%的患者中,第一次尝试就成功完成了测试.
- 所有患者均可获得生物标志物结果,中位数周转时间为7天.
- 87.7%的患者在确定生物标志物状态后立即接受了第一线治疗.
结论:
- 在临床实践中,对mGEA进行多种生物标志物测试是可行的.
- 建立一个协作,跨部门的测试基础设施对于生物标志物驱动的精密医学至关重要.
更多相关视频
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
07:35Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
相关概念视频
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Multiple Comparison Tests
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
Myocarditis II: Clinical Features and Diagnostic Tests
Pericarditis II: Clinical Features and Diagnostic Tests
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Mitral Stenosis II: Clinical features and Diagnostic Tests